BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 35269988)

  • 1. Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.
    Dobosz P; Stępień M; Golke A; Dzieciątkowski T
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
    Chen X; Zhang W; Yang W; Zhou M; Liu F
    Aging (Albany NY); 2022 Jan; 14(2):1048-1064. PubMed ID: 35037899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
    Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
    J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
    Wu J; Cai J
    Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
    Oladejo M; Paulishak W; Wood L
    Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer.
    Jin X; Liu Z; Yang D; Yin K; Chang X
    Front Immunol; 2022; 13():948647. PubMed ID: 35844558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
    Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
    Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dawn era for revisited cancer therapy by innate immune system and immune checkpoint inhibitors.
    Kim HD; Yeh CY; Chang YC; Kim CH
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167019. PubMed ID: 38211726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
    Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review.
    Dar TB; Biteghe FAN; Kakar-Bhanot R; Aniogo EC; Malindi Z; Akinrinmade OA; Chalomie NET; Kombe Kombe AJ; Aboughe Angone S; Ndong JMN; Ndong JD
    Clin Transl Oncol; 2022 Dec; 24(12):2255-2271. PubMed ID: 35913663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
    Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
    Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
    Kim CG; Sang YB; Lee JH; Chon HJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response.
    Coschi CH; Juergens RA
    Curr Oncol; 2023 Dec; 31(1):1-23. PubMed ID: 38275827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.